Glazer Capital’s Citius Oncology CTOR Stock Holding History
Bought
Maintained
Sold
Other funds holding CTOR
Glazer Capital's CTOR Position: Q3 2024 in Review
Glazer Capital sold out of Citius Oncology (CTOR) in Q3 2024, closing a stake of 306,718 shares — an estimated $3.48M sold.
Glazer Capital first reported a position in CTOR in Q4 2022 and held it in 7 quarters. The position peaked at $4.45M in Q4 2023. 7 funds tracked by Wall St. Rank hold CTOR as of Q3 2024.
- Glazer Capital reported no remaining Citius Oncology position as of Q3 2024 after selling out during the quarter.
- Glazer Capital sold 306,718 Citius Oncology shares in Q3 2024, an estimated $3.48M.
- Glazer Capital first reported a position in Citius Oncology in Q4 2022 and held it in 7 quarters.
- Glazer Capital's Citius Oncology position peaked at $4.45M in Q4 2023.
- 7 funds tracked by Wall St. Rank held Citius Oncology as of Q3 2024.
Based on Glazer Capital's 13F filing for Q3 2024, filed 14 Nov 2024.